Buys | $26,107,606 | 5 | 24 |
Sells | $298,689 | 16 | 76 |
PERCEPTIVE ADVISORS LLC | 1 | $20.15M | 0 | $0 | $20.15M | |
Bain Capital Life Sciences Investors, LLC | 10 percent owner | 1 | $4.03M | 0 | $0 | $4.03M |
Adage Capital Management, L.P. | 10 percent owner | 1 | $1.91M | 0 | $0 | $1.91M |
Kahn Clare | director | 2 | $18,366 | 0 | $0 | $18,366 |
Ganot Ilan | director | 0 | $0 | 4 | $16,547 | $-16,547 |
Herzich Paul | Chief Technology Officer | 0 | $0 | 2 | $26,195 | $-26,195 |
Tan Kevin | CFO & Treasurer | 0 | $0 | 2 | $28,379 | $-28,379 |
Brooks Gabriel | Chief Medical Officer | 0 | $0 | 2 | $31,893 | $-31,893 |
Hanrahan Jessie | Chief Regulatory Officer | 0 | $0 | 2 | $38,015 | $-38,015 |
Howton David T | Chief Operating Officer | 0 | $0 | 2 | $50,418 | $-50,418 |
Cumbo Alexander | President and CEO | 0 | $0 | 2 | $107,242 | $-107,242 |
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one …
Over the last 12 months, insiders at Solid Biosciences Inc. have bought $26.11M and sold $298,689 worth of Solid Biosciences Inc. stock.
On average, over the past 5 years, insiders at Solid Biosciences Inc. have bought $35.12M and sold $297,764 worth of stock each year.
Highest buying activity among insiders over the last 12 months: PERCEPTIVE ADVISORS LLC () — $20.15M. Bain Capital Life Sciences Investors, LLC (10 percent owner) — $4.03M. Adage Capital Management, L.P. (10 percent owner) — $1.91M.
The last purchase of 1,860 shares for transaction amount of $9,924 was made by Kahn Clare (director) on 2025‑03‑11.
2025-03-11 | Kahn Clare | director | 1,860 0.0023% | $5.34 | $9,924 | -8.20% | ||
2025-02-19 | PERCEPTIVE ADVISORS LLC | 5M 9.5155% | $4.03 | $20.15M | -8.74% | |||
2025-02-19 | Bain Capital Life Sciences Investors, LLC | 10 percent owner | 1M 1.9031% | $4.03 | $4.03M | -8.74% | ||
2025-02-18 | Adage Capital Management, L.P. | 10 percent owner | 252,545 1.1857% | $7.56 | $1.91M | -9.17% | ||
2025-02-14 | Sale | Cumbo Alexander | President and CEO | 11,365 0.0286% | $3.96 | $45,005 | +35.98% | |
2025-02-14 | Sale | Tan Kevin | CFO & Treasurer | 3,164 0.008% | $3.96 | $12,529 | +35.98% | |
2025-02-14 | Sale | Howton David T | Chief Operating Officer | 5,561 0.014% | $3.96 | $22,022 | +35.98% | |
2025-02-14 | Sale | Brooks Gabriel | Chief Medical Officer | 3,256 0.0082% | $3.96 | $12,894 | +35.98% | |
2025-02-14 | Sale | Hanrahan Jessie | Chief Regulatory Officer | 3,079 0.0077% | $3.96 | $12,193 | +35.98% | |
2025-02-14 | Sale | Herzich Paul | Chief Technology Officer | 2,688 0.0068% | $3.96 | $10,644 | +35.98% | |
2025-02-14 | Sale | Ganot Ilan | director | 1,711 0.0043% | $3.96 | $6,776 | +35.98% | |
2025-01-28 | Sale | Ganot Ilan | director | 144 0.0003% | $3.11 | $448 | +56.63% | |
2025-01-10 | Sale | Tan Kevin | CFO & Treasurer | 4,073 0.0109% | $3.89 | $15,849 | -0.54% | |
2025-01-06 | Sale | Ganot Ilan | director | 1,056 0.0028% | $4.31 | $4,551 | -7.32% | |
2024-12-03 | Sale | Cumbo Alexander | President and CEO | 11,114 0.0299% | $5.60 | $62,236 | -20.46% | |
2024-12-03 | Sale | Howton David T | Chief Operating Officer | 5,072 0.0136% | $5.60 | $28,396 | -20.46% | |
2024-12-03 | Sale | Hanrahan Jessie | Chief Regulatory Officer | 4,610 0.0124% | $5.60 | $25,822 | -20.46% | |
2024-12-03 | Sale | Herzich Paul | Chief Technology Officer | 2,777 0.0075% | $5.60 | $15,551 | -20.46% | |
2024-10-21 | Sale | Brooks Gabriel | Chief Medical Officer | 2,923 0.0085% | $6.50 | $19,000 | -13.23% | |
2024-06-07 | Kahn Clare | director | 1,100 0.0027% | $7.67 | $8,442 | -27.30% |
PERCEPTIVE ADVISORS LLC | 11833539 15.2705% | $60.23M | 5 | 0 | <0.0001% | |
Bain Capital Life Sciences Investors, LLC | 10 percent owner | 5034582 6.4968% | $25.63M | 1 | 0 | |
Adage Capital Management, L.P. | 10 percent owner | 4248084 5.4819% | $21.62M | 1 | 0 | |
Kahn Clare | director | 2960 0.0038% | $15,066.40 | 2 | 0 | |
RA CAPITAL MANAGEMENT, L.P. | 4192216 5.4098% | $21.34M | 2 | 0 | <0.0001% |
$14,527,743 | 76 | 38.40% | $447.93M | |
$84,871,118 | 57 | 17.71% | $412.59M | |
$26,923,982 | 20 | -17.22% | $407.13M | |
$73,222,926 | 18 | 60.19% | $406.4M | |
$14,865,077 | 18 | -28.56% | $389.16M |
Increased Positions | 51 | +54.84% | 4M | +10.69% |
Decreased Positions | 37 | -39.78% | 3M | -9.34% |
New Positions | 16 | New | 795,664 | New |
Sold Out Positions | 18 | Sold Out | 1M | Sold Out |
Total Postitions | 107 | +15.05% | 36M | +1.35% |
Perceptive Advisors Llc | $38,608.00 | 9.09% | 6.91M | 0 | 0% | 2024-12-31 |
Ra Capital Management, L.P. | $24,207.00 | 5.7% | 4.33M | 0 | 0% | 2024-12-31 |
Bain Capital Life Sciences Investors, Llc | $22,553.00 | 5.31% | 4.03M | 0 | 0% | 2024-12-31 |
Siren, L.L.C. | $20,957.00 | 4.93% | 3.75M | +1M | +36.38% | 2024-12-31 |
Vestal Point Capital, Lp | $15,932.00 | 3.75% | 2.85M | +50,000 | +1.79% | 2024-12-31 |
Blackrock, Inc. | $10,401.00 | 2.45% | 1.86M | +258,414 | +16.13% | 2024-12-31 |
Adage Capital Partners Gp, L.L.C. | $9,772.00 | 2.3% | 1.75M | -6,075 | -0.35% | 2024-12-31 |
Vanguard Group Inc | $7,833.00 | 1.84% | 1.4M | +30,207 | +2.2% | 2024-12-31 |
Finepoint Capital Lp | $5,373.00 | 1.27% | 961,251 | 0 | 0% | 2024-12-31 |
Jpmorgan Chase & Co | $5,344.00 | 1.26% | 955,932 | +945,863 | +9,393.81% | 2024-12-31 |